Gan & Lee Pharmaceuticals.
603087
Classificação em ações
#3014
Gan & Lee Pharmaceuticals is a biopharmaceutical enterprise primarily focused... Gan & Lee Pharmaceuticals is a biopharmaceutical enterprise primarily focused on the discovery, development, manufacturing, and marketing of insulin analogues within the Chinese market. Their diverse product portfolio encompasses injectable therapies such as Basalin (an insulin glargine), Prandilin (an insulin lispro), Prandilin 25 (another insulin lispro variant), Raplin (an insulin aspart), Raplin 30 (an insulin aspart 30 formulation), and Similin 30 (an insulin injection). Beyond diabetes treatments, the company also offers various medical devices. Established in 1998, Gan & Lee Pharmaceuticals maintains its corporate headquarters in Beijing, People's Republic of China. The organization underwent a name change in April 2005, transitioning from its former identity as Beijing Gan & Lee Biotechnology Co., Ltd.
Preço da ação
$10.03
Valor de mercado
$5.99B
Variação (1 dia)
-3.71%
Variação (1 ano)
2.30%
País
CN
Negociar Gan & Lee Pharmaceuticals. (603087)
Categoria
Healthcare
Lucros da Gan & Lee Pharmaceuticals. (603087)
Lucros em 2026 TTM: 0
De acordo com os últimos relatórios financeiros da Gan & Lee Pharmaceuticals., os ganhos atuais da empresa são de 0. Em 2026, a empresa teve ganhos de 0, igual a aos ganhos de 2026, que foram de 0. Os ganhos apresentados nesta página são os ganhos antes de juros e impostos, conhecidos como EBIT.
Histórico de lucros da Gan & Lee Pharmaceuticals. de 2013 a 2026
Lucros no final de cada ano
| Ano | Lucros | Alterar |
|---|---|---|
| 2025 | $175.78M | 103.53% |
| 2024 | $86.36M | 99.69% |
| 2023 | $43.25M | -151.22% |
| 2022 | $-84.44M | -131.65% |
| 2021 | $266.84M | 20.60% |
| 2020 | $221.27M | 10.25% |
| 2019 | $200.69M | 23.97% |
| 2018 | $161.88M | -16.93% |
| 2017 | $194.88M | 49.21% |
| 2016 | $130.61M | 61.32% |
| 2015 | $80.96M | 41.18% |
| 2014 | $57.35M | 44.07% |
| 2013 | $39.81M | 0.00% |
Lucros de empresas semelhantes ou concorrentes
| Empresa | Lucros | Diferença de Lucros | País |
|---|---|---|---|
| $3.62B | - |
US
|
|
| $4.11B | - |
FR
|
|
| - | - |
JP
|
|
| $1.59B | - |
US
|
|
| - | - |
CH
|
